工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD4 T 细胞在实体瘤排斥中的作用
英文原题：The role of CD4 T cells in rejection of solid tumors.
查看英文原题
The role of CD4 T cells in rejection of solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症免疫治疗的重点主要放在 CD8 T 细胞上，因为它们能直接识别癌细胞。CD4 T 细胞在很大程度上被忽视，因为大多数癌症缺乏 MHC II 表达，无法被 CD4 T 细胞直接识别。然而，肿瘤抗原可以被表达 MHC II 的肿瘤基质细胞捕获并交叉呈递。近期数据表明，CD4 T 细胞如同对抗肿瘤的瑞士军刀。如果癌细胞表达 MHC II，它们可以杀死癌细胞，诱导杀肿瘤巨噬细胞，诱导癌细胞细胞衰老，通过释放细胞因子破坏肿瘤血管，并在效应阶段帮助 CD8 T 细胞。我们预见 CD4 T 细胞在临床上的巨大前景，通过 T 细胞受体基因转移赋予其肿瘤抗原特异性，可单独使用或与工程化 CD8 T 细胞联合使用。
展开英文摘要原文
The focus in cancer immunotherapy has mainly been on CD8 T cells, as they can directly recognize cancer cells. CD4 T cells have largely been neglected, because most cancers lack MHC II expression and cannot directly be recognized by CD4 T cells. Yet, tumor antigens can be captured and cross-presented by MHC II-expressing tumor stromal cells.
Recent data suggest that CD4 T cells act as a swiss army knife against tumors. They can kill cancer cells, if they express MHC II, induce tumoricidal macrophages, induces cellular senescence of cancer cells, destroy the tumor vasculature through cytokine release and help CD8 T cells in the effector phase.
We foresee a great future for CD4 T cells in the clinic, grafted with tumor antigen specificity by T cell receptor gene transfer, either alone or in combination with engineered CD8 T cells.
论文信息
- 作者
- Poncette L、Bluhm J、Blankenstein T
- 第一作者单位
- T-knife GmbH, Robert-Rössle-Straße 10, 13125 Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany.Germany
- 通讯作者单位
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, 13125 Berlin, Germany. Electronic address: tblanke@mdc-berlin.de.Germany
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Current opinion in immunology2022 Feb
- 原文标识
- PubMed 34619457 · DOI 10.1016/j.coi.2021.09.005
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →